UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The yield of dysplasia and serrated lesions in a single-centre tertiary inflammatory bowel disease cohort

Therapeutic advances in gastroenterology, 2023-01, Vol.16, p.17562848231167280-17562848231167280

2023

Volltextzugriff (PDF)

Ileocolonic End-to-End Anastomoses in Crohn’s Disease Increase the Risk of Early Post-operative Endoscopic Recurrence in Those Undergoing an Emergency Resection

Journal of gastrointestinal surgery, 2021, Vol.25 (1), p.241-251

2021

Volltextzugriff (PDF)

Prevalence and risk factors for early medical and surgical complications following an admission for acute severe ulcerative colitis

Therapeutic advances in gastroenterology, 2023-01, Vol.16, p.17562848231215148-17562848231215148

2023

Volltextzugriff (PDF)

Swiss cheese tragedy case study

Journal of gastroenterology and hepatology, 2018-09, Vol.33 (S3), p.31-32

Thin, Lena W Y

2018

Volltextzugriff (PDF)

A High Visceral-to-Skeletal Muscle Area Ratio on Cross-Sectional Imaging Is Associated With Failure of Standard Ustekinumab Doses: A Multicenter Study

Clinical and translational gastroenterology, 2024-07, Vol.15 (7), p.e00722

2024

Volltextzugriff (PDF)

The Effect of Adiposity on Anti-Tumor Necrosis Factor-Alpha Levels and Loss of Response in Crohn's Disease Patients

Clinical and translational gastroenterology, 2020-09, Vol.11 (9), p.e00233-e00233

2020

Volltextzugriff (PDF)

Oral tacrolimus for the treatment of refractory inflammatory bowel disease in the biologic era

Inflammatory bowel diseases, 2013-06, Vol.19 (7), p.1490-1498

2013

Volltextzugriff (PDF)

IgG4-related sclerosing disease of the small bowel presenting as necrotizing mesenteric arteritis and a solitary jejunal ulcer

The American journal of surgical pathology, 2012-06, Vol.36 (6), p.929-934

2012

Volltextzugriff (PDF)

Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab

Medical journal of Australia, 2021-11, Vol.215 (9), p.435-435

2021

Volltextzugriff (PDF)

Editorial: outcomes following a second switch—evaluating clinical outcomes and patient perspectives in IBD

Alimentary pharmacology & therapeutics, 2021-05, Vol.53 (9), p.1038-1039

2021

Volltextzugriff (PDF)

Colonic endometriosis with malignant transformation mimicking a diverticular abscess

International journal of colorectal disease, 2008-08, Vol.23 (8), p.821-822

2008

Volltextzugriff (PDF)

Distribution of Serum Testosterone Concentrations in IBD Males and Associations With Inflammatory Bowel Disease Activity

Inflammatory bowel diseases, 2024-08

2024

Volltextzugriff (PDF)

Tu1716 UPADACITINIB THERAPY REDUCES CROHN'S DISEASE SYMPTOMS WITHIN THE FIRST WEEK OF INDUCTION THERAPY

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-1091-S-1091

2023

Volltextzugriff (PDF)

Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study

Medical journal of Australia, 2021-02, Vol.214 (3), p.128-133

2021

Volltextzugriff (PDF)

Mo1722 REDUCTION OF BOWEL WALL THICKNESS AND DOPPLER SIGNALS AS EARY AS 36 HOURS PREDICTS CORTICOSTEROID RESPONSE IN A MULTI-CENTRE PROSPECTIVE COHORT OF ACUTE SEVERE ULCERATIVE COLITIS: USUC STUDY INCLUDING GENIUS COHORT

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-879-S-880

2023

Volltextzugriff (PDF)

Upadacitinib Reduces Crohn’s Disease Symptoms Within the First Week of Induction Therapy

Clinical gastroenterology and hepatology, 2024-08, Vol.22 (8), p.1668-1677

2024

Volltextzugriff (PDF)

Higher Anti-tumor Necrosis Factor-α Levels Correlate With Improved Radiologic Outcomes in Crohn’s Perianal Fistulas

Clinical gastroenterology and hepatology, 2022-06, Vol.20 (6), p.1306-1314

2022

Volltextzugriff (PDF)

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

Gastroenterology (New York, N.Y. 1943), 2023-12, Vol.165 (6), p.1443-1457

2023

Volltextzugriff (PDF)

Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford

World journal of gastroenterology : WJG, 2020-08, Vol.26 (30), p.4428-4441

2020

Volltextzugriff (PDF)

Su437 HIGHER ANTI-TUMOUR NECROSIS FACTOR-ALPHA DRUG LEVELS ARE ASSOCIATED WITH IMPROVED RADIOLOGICAL OUTCOMES IN PATIENTS WITH PERIANAL FISTULISING CROHN'S DISEASE: A MULTICENTRE CROSS-SECTIONAL RETROSPECTIVE STUDY

Gastroenterology (New York, N.Y. 1943), 2021-05, Vol.160 (6), p.S-688-S-689

2021

Volltextzugriff (PDF)

Entyvio lengthen dose-interval study: lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel disease

European journal of gastroenterology & hepatology, 2018-07, Vol.30 (7), p.735-740

2018

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(29)
Berichte
(1)

Sprache

Englisch
(30)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

The yield of dysplasia and serrated lesions in a single-centre tertiary inflammatory bowel disease cohort

Ileocolonic End-to-End Anastomoses in Crohn’s Disease Increase the Risk of Early Post-operative Endoscopic Recurrence in Those Undergoing an Emergency Resection

Prevalence and risk factors for early medical and surgical complications following an admission for acute severe ulcerative colitis

Swiss cheese tragedy case study

A High Visceral-to-Skeletal Muscle Area Ratio on Cross-Sectional Imaging Is Associated With Failure of Standard Ustekinumab Doses: A Multicenter Study

The Effect of Adiposity on Anti-Tumor Necrosis Factor-Alpha Levels and Loss of Response in Crohn's Disease Patients

Oral tacrolimus for the treatment of refractory inflammatory bowel disease in the biologic era

IgG4-related sclerosing disease of the small bowel presenting as necrotizing mesenteric arteritis and a solitary jejunal ulcer

Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial

Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab

Editorial: outcomes following a second switch—evaluating clinical outcomes and patient perspectives in IBD

Colonic endometriosis with malignant transformation mimicking a diverticular abscess

Distribution of Serum Testosterone Concentrations in IBD Males and Associations With Inflammatory Bowel Disease Activity

Tu1716 UPADACITINIB THERAPY REDUCES CROHN'S DISEASE SYMPTOMS WITHIN THE FIRST WEEK OF INDUCTION THERAPY

Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study

Mo1722 REDUCTION OF BOWEL WALL THICKNESS AND DOPPLER SIGNALS AS EARY AS 36 HOURS PREDICTS CORTICOSTEROID RESPONSE IN A MULTI-CENTRE PROSPECTIVE COHORT OF ACUTE SEVERE ULCERATIVE COLITIS: USUC STUDY INCLUDING GENIUS COHORT

Upadacitinib Reduces Crohn’s Disease Symptoms Within the First Week of Induction Therapy

Higher Anti-tumor Necrosis Factor-α Levels Correlate With Improved Radiologic Outcomes in Crohn’s Perianal Fistulas

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

Tu1749 POST-USTEKINUMAB INDUCTION IL-12, IL-23, AND USTEKINUMAB LEVELS ARE ASSOCIATED WITH CLINICAL RESPONSE IN A MULTICENTRE PROSPECTIVE COHORT STUDY OF CROHN'S DISEASE PATIENTS: RESULTS FROM THE AURORA STUDY

Su1733 BASELINE CYTOKINE LEVELS AND MICROBIOME SIGNATURES ARE ASSOCITED WITH CLINICAL RESPONSE FOLLOWING USTEKINUMAB INDUCTION IN A MULTI-CENTRE PROSPECTIVE COHORT STUDY OF CROHN'S DISEASE PATIENTS: RESULTS FROM THE AURORA STUDY

Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford

Su437 HIGHER ANTI-TUMOUR NECROSIS FACTOR-ALPHA DRUG LEVELS ARE ASSOCIATED WITH IMPROVED RADIOLOGICAL OUTCOMES IN PATIENTS WITH PERIANAL FISTULISING CROHN'S DISEASE: A MULTICENTRE CROSS-SECTIONAL RETROSPECTIVE STUDY

Entyvio lengthen dose-interval study: lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel disease

High Technical Success Rate of Endoscopic Balloon Dilatation Reduces Surgical Requirement for Patients With Stricturing Crohn’s Disease

Suchergebnisse filtern